[{"additionalPlain":"We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.\n","additional":"We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
","categories":{"commitment":"Full-Time","department":"Data Science","location":"Palo Alto, CA","team":"Data Science","allLocations":["Palo Alto, CA"]},"createdAt":1781294318936,"descriptionPlain":"About Us\n \nDELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.\n \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we:\n \nLead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.\n \nBuild With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \nPut We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.\n \nDELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA \n","description":"\n
About Us
\n
\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
\n
We're hiring an experienced data scientist to analyze and model high-dimensional molecular data across emerging data modalities in support of our oncology-focused cancer detection platform. You'll work at the intersection of cancer biology and data science, owning projects end-to-end while partnering closely with assay development and experimental teams. This is a high-impact role for someone who thrives in ambiguity and is energized by hard problems in early cancer detection.
\n
\n\n
Own end-to-end analysis of high-dimensional molecular workstreams across multiple data modalities, from data processing through interpretation and communication of results.\n
\nContribute to classifier design, development, and validation to detect cancer in prospective clinical studies
\n\n
\nAdapt external, state-of-the-art representation and foundation models for DELFI’s internal applications
\n\n
\nCollaborate closely with Assay, Software, and Clinical teams to evaluate and integrate emerging data types into analytical pipelines
\n\n
\nSupport data science coverage across active studies, including assay research, characterization and validation
\n\n
\nWork effectively in a fast-moving environment where priorities shift and self-direction is expected
\n\n\n
\n
Required
\n\n
\nDoctoral degree in Computational Biology, Bioinformatics, Data Science, or a related field with 2+ years of industry experience; or, Master's with 3+ years of industry experience; or, Bachelor’s with 5+ years of industry experience
\n\n
\nHands-on experience with high-dimensional biological datasets across multiple biomarkers and molecular data types
\n\n
\nBackground in cancer biology or oncology-focused research
\n\n
\nDemonstrated ability to own projects end-to-end with limited oversight
\n\n
\nDemonstrated ability to use experimental findings to drive decisions for future research or product directions
\n\n
\nStrong collaborator with wet lab and experimental teams
\n\n
\nProficiency in Python; experience with cloud environments (AWS preferred)
\n\n\n
Preferred
\n\n
\nExperience with cfDNA, liquid biopsy, and NGS-based platforms
\n\n
\nFamiliarity with ML modeling in a biological context
\n\n
\nExperience in a regulated diagnostics or clinical setting
\n\n\n
\n
Actual base pay will consider experience, skillset, education, and geography.
\n
\n
This role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
\n
\n
About Us
\n
\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
","categories":{"commitment":"Full-Time","department":"Assay Research & Development","location":"Palo Alto, CA","team":"Research & Development","allLocations":["Palo Alto, CA"]},"createdAt":1778704388200,"descriptionPlain":"\n \nDELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.\nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we:\nLead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.\nBuild With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \nPut We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.\n","description":"\n
\n
\n\n\n| | \n
\n\n| \n DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we: \n\n- \n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction. \n \n- \n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \n- \n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey. \n \n \n | \n
\n\n
\n
\n
As Senior Director of Assay Development, you will own all development activities across DELFI’s NGS-based cancer screening portfolio — driving the transition of innovative assays into verified, validated, and manufacturable IVD products. Reporting to the CTO, you will lead a team of scientists and functional leaders and serve as a key voice on product strategy across R&D, Quality, Regulatory, and Manufacturing.
\nThis role demands hands-on scientific judgment to know when and where to take calculated risks — and when not to — leading with science while anchoring every decision in pragmatism to keep programs moving against ambitious timelines without compromising quality or integrity.
\nThis role requires 4 days in the Palo Alto office.
"},{"text":"What you'll do ","content":"\n
\n- \n
Own end-to-end assay development strategy across all LDT and IVD programs — from study design and execution through protocol approval, analytical validation, regulatory documentation, and FDA PMA submissions
\n \n- \n
Establish and enforce compliant analytical performance claims aligned to CLIA, FDA, and international IVD standards (21 CFR Part 820, ISO 13485, ISO 14971, IVDR)
\n \n- \n
Contribute to and/or lead Formal Design Reviews at key milestones; partner with Systems Engineering to ensure product requirements are fully addressed through design verification
\n \n- \n
Oversee reagent development and qualification, automated process scale-up, and statistical process control (SPC) for lab production environments
\n \n- \n
Lead design transfer activities across programs, ensuring robust handoffs to manufacturing and sustained assay performance at commercial scale
\n \n- \n
Report directly to the CTO; lead a team of scientists and functional leaders across assay development, validation, and manufacturing readiness
\n \n- \n
Design and own the operational infrastructure for the function — scalable processes, SOPs, design control frameworks, and traceability systems aligned to 21 CFR Part 820 and ISO 13485
\n \n- \n
Apply hands-on scientific judgment to make deliberate risk decisions — knowing where to push for speed and where standards are non-negotiable — keeping programs moving against ambitious timelines without compromising quality or integrity
\n \n- \n
Represent Assay Development at the executive level; align with the CTO, VP of Regulatory & Quality, and other senior leaders on portfolio priorities and product strategy
\n \n\n
Required
\n\nPhD or MS in Molecular Biology, Biochemistry, Biomedical Engineering, Genomics, or a related discipline\n12+ years in IVD and/or LDT assay development in regulated environments\nHands-on expertise in AV and design verification of multi-marker genomic or ‘omic-based assays, with direct experience contributing to FDA regulatory submissions\nDeep knowledge of IVD regulatory frameworks: FDA 21 CFR Part 820, ISO 13485, ISO 14971, and IVDR\nProven track record designing scalable processes, SOPs, quality systems, and operational infrastructure in regulated IVD environments\nDemonstrated ownership of late-stage development programs through design transfer and manufacturing scale-up\nAbility to lead with science while anchoring in pragmatism — applying hands-on expertise to make sound risk judgments that keep programs on ambitious timelines without sacrificing rigor or compliance\n8+ years’ management experience including best practices in recruiting, coaching, performance management, and career development\nSuperb communication skills including mastery in written & oral presentations, large- and small-group forums\nStart-up mindset: passionate, innovative, accountable, able to rapidly prioritize and triage, biased to action\nProactive, decisive, and composed with a balance of high IQ & EQ\n\nPreferred
\n\nDirect leadership of FDA PMA submissions\nBackground in reagent development, critical reagent qualification, and SPC in manufacturing environments\nExperience in high-growth or scaling biotech/diagnostics companies; track record of multiple launched LDT/IVD products\n"}],"salaryRange":{"min":275000,"max":310000,"currency":"USD","interval":"per-year-salary"},"salaryDescription":"Actual base pay will consider experience, skillset, education, and geography.
\n
\nThis role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
","salaryDescriptionPlain":"Actual base pay will consider experience, skillset, education, and geography.\n \nThis role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.\n","text":"Senior Director, Assay Development","country":"US","workplaceType":"onsite","opening":"","openingPlain":"","descriptionBody":"\n
\n
\n\n\n| | \n
\n\n| \n DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we: \n\n- \n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction. \n \n- \n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \n- \n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey. \n \n \n | \n
\n\n
\n
\n
\n
About Us
\n
\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
The Sr. Director, Clinical Development provides leadership across DELFI's clinical study portfolio, working closely with senior leadership and cross-functional teams including R&D, medical, quality, and regulatory. This leader helps to direct the comprehensive strategy for all DELFI clinical studies and to execute on our key trials supporting product development, launch, and reimbursement. We seek an adaptable, rigorous, and collaborative leader who is solidly grounded in clinical development. The role requires technical expertise in clinical study development and operations, oncology, and preferably diagnostics product development.
"},{"text":"What You'll Do ","content":"\n
Clinical Study Development & Operations
\n\n
\nDevelop and execute clinical studies that generate robust evidence for DELFI's current and future pipeline of product claims, including studies that establish clinical validity and clinical utility.
\n\n
\nAdvance DELFI's development of diagnostic products for cancer, with the detection of lung cancer in USPSTF-eligible individuals as the first indication.
\n\n
\nPlay a key role in implementing the five-year clinical development strategy based on the latest clinical science, evidence gaps, and unmet needs in cancer diagnostics.
\n\n
\nPartner with R&D Biostatistics to design case-control and prospective clinical studies, and to analyze those studies in accordance with statistical analysis plans and study protocols.
\n\n
\nManage the clinical development & clinical operations groups and affiliated CROs and investigators, including vendor selection/management/monitoring, site selection, patient enrollment and follow-up.
\n\n
\nDevelop and manage clinical trial timelines, budget, and risks in accordance with overall product development processes and plans.
\n\n\n
Regulatory & Evidence Management
\n\n
\nInteract with FDA on submissions for IVD product approval, including face-to-face/virtual meetings and written presubmissions in coordination with Regulatory Affairs.
\n\n
\nAuthor relevant sections of IVD documents pertaining to clinical development activities, design controls, requirements, etc.
\n\n
\nWork closely with Medical Affairs to identify evidence gaps and generate real-world data for DELFI's product(s).
\n\n
\nCollaborate with Data Engineering to store, curate, and cross-reference DELFI's clinical data.
\n\n\n
Communication, Thought Leadership & Outreach
\n\n
\nParticipate in industry stakeholder groups and consortia such as BLOODPAC or the Global Alliance for Genomics and Health.
\n\n
\nPresent to senior leadership, company-wide, and at key national scientific and clinical meetings.
\n\n\n
\n
Required
\n\n
\nPhD in the physical or natural sciences, or MD. Disciplinary expertise in cancer biology strongly preferred.
\n\n
\n8+ years' expertise leading the design & development of clinical studies for either pharmaceutical or diagnostics development, as evidenced by a strong publication record or successful product releases.
\n\n
\n3–5 years' experience in IVD diagnostics development.
\n\n
\nKnowledge of relevant clinical & regulatory standards such as ICH E6(R3) GCP, ISO 14155, ISO 13485, 21 CFR Part 820.
\n\n
\n6–8 years' management experience including best practices in recruiting, coaching, performance management, and career development.
\n\n
\nExcellent communication skills including mastery in written & oral presentations, large- and small-group forums.
\n\n
\nStart-up mindset: passionate, innovative, accountable, able to rapidly prioritize and triage, biased to action.
\n\n
\nProactive, decisive, and composed with a balance of high IQ & EQ.
\n\n\n
Preferred
\n\n
\nFamiliarity with cutting-edge AI approaches in clinical trials (NLP or LLM for EHRs, digital twins, digital pathology) as well as international data standards such as FAIR principles, FHIR-OMOP, or Common Data Models.
\n\n\n
Actual base pay will consider experience, skillset, education, and geography.
\n
\nThis role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
","salaryDescriptionPlain":"Actual base pay will consider experience, skillset, education, and geography. \n \nThis role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.\n","text":"Senior Director, Clinical Development","country":"US","workplaceType":"hybrid","opening":"","openingPlain":"","descriptionBody":"\n
About Us
\n
\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
","categories":{"commitment":"Full-Time","department":"Software Engineering & IT","location":"Palo Alto, CA","team":"Software Engineering","allLocations":["Palo Alto, CA"]},"createdAt":1778705542226,"descriptionPlain":"DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.\nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we:\nLead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.\nBuild With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class\nPut We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.\nDELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA \n","description":"\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n- Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n- Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n- Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
\n
In this role, you'll be a senior technical leader on our bioinformatics pipeline team, contributing to long-term technical direction and architectural decisions for major systems with a focus on software and cloud architecture. You'll partner across Engineering, Data Science, R&D, Regulatory, and Project Management to translate strategy into executable technical plans.
\n
\nThis role sits at the intersection of deep technical expertise, design control rigor, and cross-functional leadership. We seek a leader who can hold the long view while still going deep on the hardest technical problems, and who elevates the team through the standards and systems they build.
"},{"text":"What you'll do ","content":"\n
Strategy & Architecture
\n\n
\nSet long-term technical strategy and architectural vision for our bioinformatics pipeline systems, ensuring today's decisions support tomorrow's product roadmap.
\n\n
\nLead system architecture and high-stakes design reviews end-to-end, guiding the team through the most complex technical tradeoffs.
\n\n
\nDesign and own data hand-off and integration architecture between software systems.
\n\n\n
Engineering Standards & Process
\n\n
\nServe as a leader in engineering best practices—establishing standards, driving software-development lifecycle (SDLC) rigor, and setting the bar for code quality, testing, and design across the team.
\n\n
\nDrive requirements engineering, risk analysis, and verification strategies for regulated software components.
\n\n
\nPartner with staff engineers on test design and execution, driving excellence in SDLC process implementation.
\n\n\n
Operations & Delivery
\n\n
\nArchitect and own the DevOps strategy for the pipeline team, including cybersecurity, CI/CD, infrastructure-as-code, deployment automation, observability, and environment management, ensuring reliability and compliance in a regulated context.
\n\n
\nWork with data scientists, lab staff, and other stakeholders to implement production software for diagnostic applications.
\n\n\n
Leadership
\n\n
\nPartner with our Program Management team and engineering leadership on roadmap planning, milestone definition, resourcing, dependency management, and risk tracking across multi-quarter initiatives.
\n\n
\nMentor and develop staff and senior engineers, raising the team's technical ceiling and cultivating the next generation of technical leaders.
\n\n
\nServe as a recognized technical authority across the organization, influencing product and platform direction without direct authority over teams or roadmaps.
\n\n\n
\n
Required
\n\n
\nBachelor's degree in Computer Science, Mathematics, Data Science, or related field
\n\n
\nRelevant professional experience dependent on level of education:
\n\n\nBS: 10+ years, MS: 8+ years, Ph.D: 5+ years
\n\n\n\n
\nExcellent verbal and written communication skills, including proficiency in public speaking and technical presentation
\n\n
\nExposure to the life sciences industry, including DNA sequencing, quantitative genetics, bioinformatics, or data science
\n\n
\nDemonstrated experience setting long-term technical strategy and architectural standards across multi-team or multi-system scope
\n\n
\nAdvanced knowledge of cloud computing infrastructure design and implementation for scalable high-performance computing applications (AWS preferred)
\n\n
\nExpertise in Python and strong proficiency in at least one compiled language (Rust, Java, C++, or C#)
\n\n
\nStrong software design skills
\n\n
\nExperience designing data integration patterns and contracts between software systems
\n\n
\nStrong command of agile development practices, Jira, Git, and modern CI/CD pipelines
\n\n\n
Preferred
\n\n
\nWorking knowledge of regulated software development standards (IEC 62304, ISO 13485, FDA 21 CFR Part 11, and ISO 14971)
\n\n
\nExperience working at an early-stage or high-growth company where the environment moves fast
\n\n\n
\n
Actual base pay will consider experience, skillset, education, and geography. This role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
\n
\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n- Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n- Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n- Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
\n
DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA
\n
\n
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
","categories":{"commitment":"Full-Time","department":"Data Science","location":"Palo Alto, CA","team":"Data Science","allLocations":["Palo Alto, CA"]},"createdAt":1778798019804,"descriptionPlain":"DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.\nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we:\nLead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.\nBuild With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \nPut We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.\nDELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA \n","description":"\n
\n
\n
\n\n\n| \n DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we: \n\n- \n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction. \n \n- \n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \n- \n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey. \n \n \n\n DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA \n | \n
\n\n
\n
\n
\n
\n
We're hiring an experienced statistician to play a key role in the analytical validation of our cancer detection assays, partnering across assay development, lab operations, software, regulatory, and data science. The ideal candidate will provide statistical leadership on complex AV problems, set standards for how studies are designed and analyzed at DELFI, and mentor junior team members.
\n
\n\n
\nDesign and execute analytical validation studies across our assay development pipeline, partnering with lab, software, regulatory, and data science teams.
\n\n
\nApply and develop statistical methods suited to NGS-based assays and liquid biopsy platforms.
\n\n
\nDefine and apply rigorous, pre-specified acceptance criteria and sample size calculations for assay performance.
\n\n
\nAuthor statistical analysis plans, study reports, and regulatory submissions for both LDT and IVD pathways, and serve as an internal statistical consultant across functions.
\n\n
\nFamiliarity with IVD regulatory requirements and analytical validation standards (e.g., CLSI guidelines, FDA 21 CFR Part 820, ISO 13485, IVDR).
\n\n
\nProvide statistical leadership on complex or novel analytical validation problems, set standards for how AV studies are designed and analyzed at DELFI, and mentor junior team members.
\n\n\n
\n
Required
\n\n
\nDoctoral degree in Statistics, Biostatistics, or a related field with 2+ years of industry experience; or Master's with 5+ years of industry experience
\n\n
\nExperience designing and analyzing applied statistical studies in analytical validation
\n\n
\nProficiency in R, Python is a plus
\n\n
\nStrong written and verbal communication, including translating statistical reasoning for non-statistical audiences.
\n\n
\nStrong critical thinking, ability to manage multiple priorities independently, and a collaborative working style.
\n\n
\nAssay validation experience in a regulated environment (LDT or IVD), and familiarity with relevant CLSI guidelines.
\n\n\n
Preferred
\n\n
\nExperience with NGS-based assays or liquid biopsy platforms.
\n\n
\nExperience with FDA pre-submission meetings or direct agency interactions.
\n\n
\nAbility to develop novel statistical methods from first principles.
\n\n
\nPublications or presentations in diagnostic statistics, analytical validation or clinical validation.
\n\n\n
\n
Actual base pay will consider experience, skillset, education, and geography.
\n
\n
This role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
\n
\n
\n
\n
\n\n\n| \n DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we: \n\n- \n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction. \n \n- \n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \n- \n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey. \n \n \n\n DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto, CA \n | \n
\n\n
\n
\n
\n
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
","categories":{"commitment":"Full-Time","department":"Assay Research & Development","location":"Palo Alto, CA","team":"Research & Development","allLocations":["Palo Alto, CA"]},"createdAt":1778706486699,"descriptionPlain":"DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.\n \nIn our passionate pursuit to radically improve health outcomes, we serve humanity when we:\n \nLead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.\n \nBuild With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class \n \nPut We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.\n","description":"\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n
\n
In this role, you will support the verification and validation of an automated IVD Next-Generation Sequencing-based assay under development for early cancer detection. Reporting directly to the Principal Scientist leading the analytical validation (AV) program, you will contribute to the design, execution, and documentation of design verification studies that will serve as the basis for the assay’s analytical performance claims. You will collaborate closely with quality and regulatory functions to help ensure that product design, development, and transfer comply with design control and risk management requirements.
\n
\n\n
\nSupport Delfi’s culture of compliance by contributing to scalable tools, structures, and processes for compliant product development.
\n\n
\nAssist in the verification and validation of products compliant with CLIA, FDA, and international regulatory standards, under the direction of the Principal Scientist.
\n\n
\nContribute to the execution of Delfi’s design control process throughout all stages of the product life cycle.
\n\n
\nDesign, plan, and execute analytical validation (AV) studies, other design verification studies, and design transfer activities as assigned by the Principal Scientist.
\n\n
\nCollaborate with R&D, Lab Operations, Biostatisticians, and Quality and Regulatory teams to execute study plans.
\n\n
\nPrepare design verification and validation study documentation, including study protocols and reports.
\n\n
\nContribute to FDA PMA submission packages under the guidance of the Principal Scientist.
\n\n
\nPrepare and present data at Formal Design Reviews and key program milestones.
\n\n
\nCollaborate with Systems Engineering to document product requirements and support design verification activities that confirm requirements are met.
\n\n\n
\n
Required
\n\n
\nDoctoral degree in Molecular Biology, or a related field with 4+ years of relevant work experience; or Master’s degree with 7+ years of relevant work experience; or Bachelor’s degree with 9+ years of relevant work experience; or equivalent.
\n\n
\n2+ years of experience developing IVD products in regulated environments
\n\n
\nWorking knowledge of IVD regulatory requirements (FDA 21 CFR Part 820, ISO14971, ISO13485, IVDR).
\n\n
\nHands-on IVD and analytical validation experience with genomic or multi-marker ‘omic assays.
\n\n
\nStrong analytical skills with the ability to solve complex technical problems.
\n\n
\nProven ability to collaborate cross-functionally and communicate effectively with technical and non-technical stakeholders.
\n\n\n
Preferred
\n\n
\nExperience with design transfer and/or manufacturing of IVD products.
\n\n
\nExposure to or direct participation in PMA submissions.
\n\n\n
Actual base pay will consider experience, skillset, education, and geography. This role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.
","salaryDescriptionPlain":"Actual base pay will consider experience, skillset, education, and geography. This role may be eligible for other forms of compensation, including an annual bonus and a new hire equity grant, subject to the terms of the applicable plans and Company discretion. All employees are also eligible for DELFI's comprehensive and competitive benefits package, including but not limited to: a flexible time-off policy; a 401(k) retirement plan; an extremely competitive medical, dental, and vision coverage; onsite lunch 3 days a week; and other wellness related offerings.\n","text":"Staff Scientist, IVD Assay Verification and Validation","country":"US","workplaceType":"onsite","opening":"","openingPlain":"","descriptionBody":"\n
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI (\"DNA EvaLuation of Fragments for early Interception\") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
\n
\n
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
\n
\n
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
\n
\n
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
\n
\n
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
\n